Distant delivery of a mindfulness-based intervention for people with Parkinson's disease:the study protocol of a randomized pilot trial by Bogosian, Angeliki et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1186/s40814-016-0117-4
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Bogosian, A., Hurt, C. S., Vasconcelos e Sa, D., Hindle, J. V., McCracken, L., & Cubi-Molla, P. (2017). Distant
delivery of a mindfulness-based intervention for people with Parkinson's disease: the study protocol of a
randomized pilot trial. Pilot and Feasibility Studies, 3(4), 4. DOI: 10.1186/s40814-016-0117-4
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 23. Jan. 2018
STUDY PROTOCOL Open Access
Distant delivery of a mindfulness-based
intervention for people with Parkinson’s
disease: the study protocol of a
randomised pilot trial
A. Bogosian1*, C. S. Hurt1, D. Vasconcelos e Sa1, J. V. Hindle2, L. McCracken3 and P. Cubi-Molla4
Abstract
Background: Psychological difficulties, especially depression and anxiety, are the most prevalent non-motor
symptoms in Parkinson’s disease. Pharmacological treatments for these conditions appear relatively ineffective
in Parkinson’s disease. Mindfulness courses are increasingly popular and recognised as effective for managing
emotional states, and there is growing evidence for the effectiveness of mindfulness courses for people with
long-term medical conditions. With this exploratory pilot trial, we want to assess the feasibility of the procedures
and processes, including recruitment, most appropriate outcome measure(s), acceptability of type and number
of measures, potential nocebo effects, and potential effectiveness and cost-effectiveness of a specially adapted
distance-delivered mindfulness-based intervention in people affected by Parkinson’s disease.
Methods/Design: This is a pilot two-arm randomised parallel group controlled trial. Sixty participants who meet
eligibility criteria will be randomly assigned either to an 8-week mindfulness-based intervention group or a wait-list
control group. The mindfulness intervention will include 1-h weekly sessions delivered by a health psychologist
trained to facilitate mindfulness courses. Participants in both groups will complete standardised questionnaires
assessing anxiety, depression, pain, insomnia, fatigue, and daily activities at four time points (baseline, 4, 8, and
20 weeks). The analysis will also consider potential mechanisms of change, such as acceptance, self-compassion,
and tolerance of uncertainty, as well as health economic outcomes. Participants’ experiences of the mindfulness
interventions will be explored via in-depth interviews.
Discussion: A mindfulness-based intervention for people with Parkinson’s delivered remotely, through Skype group
videoconferences, may represent a viable, more accessible, intervention for people with mobility limitations and
people who live in rural areas. The trial will provide important information about the feasibility, potential efficacy
and cost-effectiveness, and acceptability of the intervention as well as mechanisms of psychosocial adjustment.
The results of this pilot trial will help us design a phase III trial to assess efficacy of an online mindfulness-based
intervention in Parkinson’s disease and evaluate significance.
Trial registration: ClinicalTrials.gov, NCT02683330
Keywords: Randomised controlled trial, Parkinson’s disease, Anxiety, Depression, Mindfulness
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Background
The non-motor symptoms of Parkinson’s disease (PD)
can be as disabling for an individual as their motor
symptoms, if not more so [1]. Indeed, non-motor symp-
toms dominate the clinical picture of PD and contrib-
ute to severe disability, impaired quality of life, and
shortened life expectancy [2]. Anxiety and depression
are the most prevalent non-motor symptoms in PD.
Depending on the criteria used, depression affects up
to 50% of people affected by PD [3] and up to 31% of
people with PD report some level of anxiety [4]. Even
when people do not experience significant psycho-
logical disorders, they may still struggle to adjust to the
social, emotional, and personal changes brought on by
the condition.
Pharmacological interventions for anxiety and depres-
sion have received the most empirical attention to date.
However, people with PD benefit less from antidepressant
treatment than do patients without PD [5]. Also, there is a
high risk of negative side effects and adverse interactions
between antidepressants and antiparkinsonian medica-
tions [6]. Anxiety is managed pharmacologically largely
also by antidepressants [7]. Atomoxetine, an effective drug
treatment for anxiety in non-PD patients, was not found
to be efficacious for anxiety in PD [8]. Benzodiazepines,
commonly used for anxiety disorder treatment, are not
recommended for PD patients due to adverse effects
including cognitive and psychomotor impairment [9].
Therefore, non-pharmacological interventions can provide
a good alternative for mood problems in PD.
To date, there is very little research into the effective-
ness of psychological interventions in PD, with only a
small number of studies [10–12] investigating the feasi-
bility and effectiveness of cognitive behavioural therapy
(CBT) in the treatment of depression and anxiety.
Mindfulness-based group therapy is a rapidly growing
psychological approach to helping people adjust to
chronic illness and manage unpleasant symptoms that
is embedded within the concept of acceptance. Mind-
fulness focuses on finding a new way to relate to
thoughts and to accept them as passing events that do
not necessarily represent a state of reality [13]. Mind-
fulness is based on the philosophy that human suffering
develops in part by efforts to struggle with and avoid
our own psychological and emotional pain. Changing
one’s relationship to thoughts appears to be the most
effective component of mindfulness-based intervention
[13]. Over a typical 8-week mindfulness course, partici-
pants complete daily mindfulness meditation practices
and attend weekly group meetings.
Furthermore, mindfulness has potential cost advan-
tages as interventions are delivered to groups requiring
less therapist time per patient. Mindfulness courses have
clear time boundaries, and once the techniques have
been taught, patients can continue practising without
additional contribution from a therapist.
A 2005 meta-analysis of the health benefits of mind-
fulness across a range of chronic illnesses suggested
that mindfulness is at least moderately effective at im-
proving symptom management, anxiety, and depression
in a range of conditions [14]. Three recent small rando-
mised control trials (n = 29, 30, and 14) showed a signifi-
cant decrease after the mindfulness-based intervention in
reported motor symptoms [15, 16] and symptoms of de-
pression [16, 17] and anxiety [16] for people with PD. A
qualitative study evaluating the acceptability and feasibility
of this approach in a group of patients with PD [18] has
found that this form of intervention is well accepted by
patients with PD. Further, an MRI study showed that
mindfulness in PD leads to structural brain changes [19].
Increased grey matter density was found in the mindful-
ness group compared to the usual-care group in the right
amygdala and bilaterally in the hippocampus [19]. These
areas have been postulated to play an important role in
PD as they seem to contribute to clinical motor symptoms
(bradykinesia, tremor, rigidity) and non-motor symptoms.
To date, there is very little research in evaluating the
effects of mindfulness in reducing anxiety and depres-
sion in patients with PD. Given the body of evidence
exposed above, it would be realistic to expect that a
mindfulness-based intervention could be beneficial for
people with PD in relation to issues such as denial and
acceptance of the illness, the loss of independence, and
the many disturbances that go together with a disease
over which the person has limited control.
We propose to deliver a mindfulness intervention via
Skype, an online application that enables videoconfer-
ences with two or more people. Online mindfulness
courses might facilitate attendance and adherence in
this particular population [17]. There has been increas-
ing use of distance-delivered interventions for people
with disease-related barriers such as impaired mobility.
Further, there is evidence that distance-delivered mind-
fulness interventions can also be effective in people
with chronic medical conditions [20–23].
We ran two patient advisory group meetings (n = 14)
with people with PD in preparation for this trial.
Participants of these meetings were recruited through
Parkinson’s UK research network and most had some
knowledge of mindfulness and its application. The first
and second authors facilitated the groups. We talked
to participants about our plans with the trial and the
development of the intervention, and here, we incor-
porated their feedback. The focus group participants
talked about mindfulness being beneficial to people
who do not necessarily experience high levels of anxiety
or depression but still they have difficulties adjusting to
PD challenges and managing PD symptoms. Participants
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also reported that although using Skype may exclude
people not familiar with technology or people who do not
own a computer, this method of delivery would make it
possible for people across the country and those with re-
stricted mobility to participate. Patient advisory group par-
ticipants were overall in favour of using Skype and as one
participant said ‘we need to move with the times, we need
to go with the technology’.
Aims
The overall objective of this study is to assess the feasibil-
ity of procedures and processes as well as potential effi-
cacy (i.e. explore potential for detecting change in each of
the proposed measures for each group) of a mindfulness-
based intervention (MBI) for people with PD, which will
be delivered via Skype.
The specific aims of this trial are to:
1. Monitor rates of recruitment, retention, refusal,
adherence to the mindfulness sessions, and
homework practice, as well as the appropriateness of
eligibility criteria to determine the rate of each for
planning the main trial
2. Assessing time and resource problems, for example
whether it is feasible for patients to answer all the
questionnaires and the time taken to do so, the flow
of participants entering the study, the use of equipment
to set up Skype, and other resources needed
3. Determine data management issues, by monitoring
levels of missing data and data variability
4. Evaluate the potential for detecting a change in each
of the proposed outcome measures (anxiety,
depression, pain, fatigue, insomnia, quality of life,
subjective well-being, physical impact of PD, health
costs) when comparing the mindfulness-based inter-
vention (MBI) group to the wait-list control (WLC)
group
5. Understand the mechanisms of change (mindfulness
skills, acceptance, self-compassion, decentering,
tolerance of uncertainty) in each patient group,
including any potential nocebo effects in the WLC
group
6. Assess the qualitative experiences of receiving the
mindfulness intervention and people’s views and
experiences of using Skype as a mode of delivery as
well as people’s feedback on the questionnaires used
Methods/Design
Design and theoretical framework
We will use a parallel group randomised controlled
design. A total of 60 participants with PD will be ran-
domly assigned to either an 8-week MBI course (n = 30)
or a WLC (n = 30). CONSORT flow chart of the study is
summarised in Fig. 1.
Participants
Study sample
A pilot phase II trial of at least 30 participants is consid-
ered adequate for obtaining reasonably reliable sample
size estimates [24]. We aim to recruit 60 people affected
by PD. This sample will allow us to include six interven-
tion groups to estimate intraclass correlations that relate
to the fact that we are treating people in groups rather
than individually.
Inclusion criteria
Participants included in this study must:
 Be diagnosed with PD according to UK PD Brain
Bank Criteria [25, 26] by a neurologist or
geriatrician
 Have a computer and internet access at home
 Be able to communicate in English fluently
 Be stabilised on PD medication, antidepressants, or
anxiolytics (if taken) indicated by a stable dose for a
minimum of 1 month
Exclusion criteria
Participants will be excluded from the study if they:
 Have severe cognitive impairment that would make
participation in the mindfulness sessions and home
practice of mindful meditation problematic or
distressing. This will be assessed using the
Telephone Interview for Cognitive Status
Instrument modified version (TICS-M, [27]). People
with a score of less than 20 will be excluded.
 Have serious psychiatric conditions (e.g. psychosis,
drug/alcohol abuse) that can potentially risk failure in
the intervention or limit participation in the course.
 Have severe hearing impairment.
 Are currently participating in other psychological
therapies.
 Have prior formal training in mindfulness methods
or current meditation practice.
Recruitment and consent process
Potential participants affected by PD are recruited
through adverts on the Parkinson’s UK website and the
Michael J. Fox Foundation. Recruitment started in
February 2016 and is expected to finish in June 2016.
People with PD who see the web advert or the email
during the trial period and are interested in the study
will get in touch with the trial coordinator. Participants
will receive adequate information before consenting to
take part in the study, including information sheets and
discussion with the trial coordinator. Potential partici-
pants will be issued with a Participant Information Sheet
and will be encouraged to read it carefully and to discuss
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it with others before making a decision. Participants will
also be encouraged to contact the researchers with any
questions that they might have. In the initial discussion
with the participant, the trial coordinator will check
whether the participant has understood the purpose and
nature of the research and what the research involves,
its benefits (and lack of benefits), risks, and burdens.
After the initial discussion with the trial coordinator and
consideration of the information sheets, potential partic-
ipants will have at least 24 h to fully consider the impli-
cations of taking part in the research, ask questions, and
reflect, before giving consent. Individuals participating in
the study will sign a written consent form before the
baseline assessments. On the form, participants are
given the choice to consent to the mindfulness trial and
questionnaire assessments only or to an additional in-depth
telephone interview after their mindfulness programme has
been completed.
Eligibility screening and enrolment
During the initial telephone contact, the trial coordinator
will explain the purpose of the study in detail and poten-
tial participant’s questions will be answered. After obtain-
ing a verbal consent and explaining what will happen with
the data given in the case of eligibility/ineligibility, the trial
coordinator will administer the screening questionnaires
via telephone. After screening, participants will be notified
whether they are eligible or ineligible for the trial. If the
results of the screening assessment indicate that they are
eligible for the study, they will be given an invitation to
participate and the trial coordinator will check whether
they need any help with setting up Skype and clarify tech-
nicalities for the sessions.
Participants will be sent the equipment they need to
use Skype, such as headsets and web-cameras (if not in-
corporated in their computers) as well as a booklet with
instructions on how to set up Skype on their computer.
Fig. 1 CONSORT flowchart of trial design
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Randomisation
Participants will be randomly assigned to either the MBI
group or the WLC group with a 1:1 allocation using a
computer-generated blocked randomisation scheme.
The randomisation scheme will be generated using the
randomization.com website http://www.randomization.-
com. Block randomisation will allow keeping groups in
similar sizes, ensuring a balance of numbers in each
group at any time during the trial. Six blocks of 10 par-
ticipants each will be used. The parameters will be saved
for our records.
Booking in participants’ groups
On receiving the randomisation outcome from the re-
search trial coordinator, the first author will contact the
participants to notify them of their group allocation. Par-
ticipants in the MBI group will be offered a date for
their first session. Participants in the WLC group will be
discouraged from any new mindfulness-related activities
during the trial.
Mindfulness-based intervention for PD
The MBI will be delivered in eight sessions over an 8-
week period. The sessions will last 1 h and will be held
via videoconference through Skype, an online applica-
tion, in groups of five people. The videoconferences will
be initiated by AB and will be arranged at a day and time
that is most suitable for all participants in the group.
CDs with homework mindfulness practices will address
potential issues people with PD may come across during
practices, like resting tremor, spasms, fatigue, and mind
wandering.
The sessions will be carried out based on a written
manual. However, flexibility will be allowed to follow
issues and topics that are more important for the group
during the sessions. Participants will be issued the mind-
fulness manual before their first session and will be
encouraged to read only the chapter of the relevant ses-
sion each week. The manual will contain eight chapters.
In each chapter, the homework for each week will be
outlined followed by a brief description of the week’s
theme.
Participants will sign a consent form indicating that
they understand that they are being recorded and that
recordings will be stored in password-protected files and
only be used for the stated purposes (i.e. fidelity checks
and supervision).
Developing of the MBI manual and meditation CDs—new
adaptations
The MBI manual is based on the mindfulness-based
cognitive therapy (MBCT) programme for depression
developed by Segal et al. [13]. In this study, we are using
this MBCT programme but tailored to the needs of
people with PD. One of the main changes we have in-
troduced is the reduction of time in the mindfulness
home practice. The original MBCT programme sug-
gests that participants should practise mindfulness
meditation for 45 min, 6 days a week. Due to their con-
dition, people with PD may have difficulties maintain-
ing a long practice, due to problems with sitting still in
one posture, maintaining concentration, and fatigue.
Therefore, the meditation practices were shortened to
20 min to accommodate the needs of people with PD.
Further, we have reduced the weekly group sessions
from 2/2.5 to 1 h. It has been found that the correlation
between mean effect size and the number of in-class
hours is non-significant for both clinical and nonclini-
cal samples, which suggests that adaptations that in-
clude less class time may be worthwhile for populations
for whom longer time commitment may be a barrier to
their ability to participate [28]. In fact, shortened class
time has been used successfully before, for example in
people with multiple sclerosis [23], multiple sclerosis
and peripheral neuropathy [28], and PD [17]. The man-
ual also includes PD-specific examples. These changes
will make the intervention more accessible for people
with PD without compromising its effectiveness.
MBI sessions
AB will deliver the 8-week course. AB is a health psych-
ologist, who has completed teachers’ training to deliver
mindfulness-based courses and has experience delivering
mindfulness programmes for people with neurological
conditions via Skype [23]. LM, a clinical psychologist
with experience in mindfulness programmes for people
with long-term conditions, will provide supervision.
This MBI course consists of eight sessions that cover
the following topics: (1) automatic pilot, (2) mindfulness
of breath, (3) staying present, (4) dealing with barriers,
(5) using mindfulness to respond instead of react, (6)
thoughts are not facts, (7) how can I best take care of
myself, and (8) planning for the future. For more details
on the content of the sessions, see Table 1. Recordings
of three classic meditations will be provided including
the body scan, a sitting meditation, and a mindfulness
movement meditation for daily home practice.
The sessions themselves will be based on discussion of
participants’ experiences with their meditation practice
and mindfulness concepts. Each session will start with a
short meditation practice, followed by a brief discussion
about the practice just completed and the homework
practice of the previous week. Then new concepts will
be introduced, such as acceptance, relating to thoughts,
and self-compassion. Another short meditation practice
will follow this discussion, and at the end, homework for
next week will be set.
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Table 1 Summary of the content of the MBI manual for P
Week Theme Agenda
Week 1:
Automatic pilot
Mindfulness starts when we recognise the tendency to be on
automatic pilot and make a commitment to learning how best
to step out of it to become aware of each moment. Body scan
practice trains the mind in putting attention and awareness in
different places at will. The aim of this week is to enhance
awareness.
Establish the orientation of the group
• Set ground rules regarding confidentiality and privacy
• Ask participants to introduce themselves in the group
• Raising exercise
• Discussion of raising exercise
• Body scan meditation
Homework: body scan meditation (6 out of 7 days),
mindfulness of a routine activity, eat one meal
mindfully.
Week 2:
Mindfulness of the
breath
Further focus on the body begins to show more clearly the
chatter of the mind and how it tends to control our reaction to
everyday events. The aim of this week is to enhance awareness.
• Body scan meditation
• Homework review
• Cultivating curiosity about body sensations
• Hearing meditation
Homework: body scan (6 out of 7 days), pleasant events
calendar, and mindfulness of a routine activity.
Week 3:
Staying present
Greater awareness of how the mind can get hooked in
judgements and unhelpful thoughts leads to awareness of the
impact of those thoughts and emotions on the body. In this
week, decentering is introduced.
• Mindfulness movement meditation
• Homework review
• Explain low mood/anxiety cycle and the role of
automatic thoughts
• 3-min breathing space
Homework: body scan or mindful movement
meditation for 6 days out of 7, unpleasant events
calendar, 3-min breathing space.
Week 4:
Dealing with barriers
The mind is most scattered when it tries to cling to some things
and avoid/escape other things. Mindfulness offers a way of
staying present by giving another place from which to view
things: to help take a wider perspective and relate differently to
experience. In this week, decentering is further explored and
acceptance is introduced.
• Sitting meditation
• Homework review
• Explain acceptance versus avoidance/fusion concepts
and explore unhelpful coping strategies linked to
avoidance or fusion.
• 3-min breathing space-coping
Homework: sitting meditation (6 out of 7 days), 3-min
breathing space, early warning signs and action plan
exercise.
Week 5:
Using mindfulness to
respond instead of react
Relating differently involves bringing to experience a sense of
‘allowing’ it to be, just as it is, without judging it or trying to
make it different. Such an attitude of acceptance is a major part
of taking care of oneself and seeing more clearly what, if
anything, needs to change. Acceptance is further explored, and
self-compassion is introduced.
• Sitting meditation
• Homework review
• Responding vs. reacting
• 3-min breathing space-dealing with difficulties
Homework: sitting meditation (6 out of 7 days), 3-min
breathing space.
Week 6:
Thoughts are not facts
Negative moods and the thoughts that accompany them restrict
our ability to relate differently to experience. It is liberating to
realise that our thoughts are merely thoughts, even the ones
that say they are not. This week brings together the concepts of
decentering, acceptance, and self-compassion.
• Sitting meditation
• Homework review
• Thoughts and feeling exercise (‘walking down the street’)
• Discuss how decentering and accepting can lead to
being kinder towards oneself
• 3-min breathing space
Homework: practise with a selection of meditations,
3-min breathing space.
Week 7:
How can I best take care
of myself?
There are some specific things that can be done when
distressed. Taking a breathing space will come first and then
deciding what action, if any, to take. Each person has his or her
unique warning signs of distress, but participants can help each
other in making plans of how best to respond to the signs. This
week brings together the concepts of decentering, acceptance
and self-compassion.
• Sitting meditation
• Homework review
• Generate list of pleasure and mastery activities
• Plan how best to schedule such activities
• 3-min breathing space as the first step before
choosing whether to take mindful action
Homework: Select from all different forms of practice, a
pattern you intend to use on a regular basis, 3-min
breathing space.
Week 8:
Planning for the future
Maintaining a balance in life is helped by regular mindfulness
practice. Good intentions can be strengthened by linking such
intentions to a positive reason for taking care of oneself
• Body scan meditation
• Homework review
• Review whole course: what has been learned
• Discuss how best to keep up momentum and
discipline developed over the past 7 weeks in both
formal and informal practice
• Concluding meditation
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Missed sessions and homework
AB will record attendance and make notes on participa-
tion. Details of issues covered and homework engage-
ment will be recorded as well. In the case of non-
attendance at sessions, AB will contact the participant to
ascertain the problem and to discuss a suitable solution
addressing any concerns. Unfortunately, because of the
group setting of this intervention, participants will not
have the opportunity to reschedule a missed session.
Participants will be asked to keep a diary (provided with
the manual) of their weekly homework mindfulness prac-
tices. A record of homework engagement will be kept, and
final analyses will control for homework compliance.
Wait-list control group
9pt?>Participants allocated to the WLC group will re-
ceive the treatment they would normally expect from
the National Health Service (NHS) in the UK. People
may receive a mix of clinical input and review from both
primary and secondary care providers, according to in-
dividual health needs. Access to psychological assess-
ment and intervention for people with PD is
inconsistent across the UK, and dedicated psychological
services are extremely scarce [29]. People in the WLC
group will be offered the opportunity to take part in the
MBI at the end of the 20-week follow-up.
Assessments
DVS, the trial coordinator, not involved in the therapy
sessions, will coordinate all the assessment procedures. As
shown in Table 2. Participants will be asked to complete a
set of standardised questionnaires online or on paper,
depending on their preference, at four time points (base-
line, mid- and end of the intervention, and 3 months after
completing the intervention). If participants are unable to
use a keyboard or write on paper, they will have the option
of completing assessments by telephone.
Screening measure
Telephone Interview for Cognitive Status Instrument
modified version (TICS-M, [26]). This 13-item instrument
will be used to assess cognitive status over the phone.
Although this screening tool gives particular emphasis on
learning and memory, items probing orientation, repeti-
tion, naming, and calculation are also included. The total
score ranges from 0 to 50, with higher scores indicating
better cognition. A total score cut-off of 20 will be used to
deem participants eligible to take part in the study.
Feasibility outcomes
Feasibility outcome measures have been decided following
Thabane et al. [30] recommendations.
We will compare the actual recruitment rate to the tar-
get recruitment rate, which is 10 participants per month,
and also compare the actual recruitment rate to recruit-
ment rates of psychological trials in PD. We will also
compare the retention/refusal and adherence rates to
other psychological trials in PD as well as mindfulness in-
terventions in PD delivered face-to-face. We will consider
the trial feasible if these processes compare favourably to
other psychological trials or mindfulness trials in PD. We
will also assess the appropriateness of the eligibility criteria
in recruiting a population receptive to, and appropriate for,
a mindfulness intervention by assessing adherence and re-
tention rates. We will assess whether the criteria were too
restrictive by comparing recruitment targets against actual
recruitment process and also assessing whether too many
people were excluded based on specific criteria.
We will assess time and resource problems that can
occur during the main study by assessing the length of time
required to fill out all the questionnaires. We will investi-
gate whether there is participant overload, how much time
it takes to screen participants and mail out consent forms,
whether Skype equipment is needed, and how problems
with installing or using Skype can best be managed.
We will also investigate issues around data collection,
whether data from different data points can be matched,
whether diary entries can be logged accurately, whether
there are important data variables left blank, or whether
the data show too much or too little variability.
Patient-centred outcome measures
We will explore the potential for detecting change in
each of the following outcome measures for each group
separately.
Hospital Anxiety and Depression Scale (HADS, [31])
This 14-item scale will be used to assess symptoms of de-
pression (7 items) and anxiety (7 items). This scale has been
found to be effective in assessing the symptoms of the sever-
ity of anxiety and depression in both secondary and primary
care patients [32]. Each item is scored on a scale of 0–3,
with 3 indicating higher symptom frequencies. Scores for
each subscale (anxiety and depression) range from 0 to 21.
A cut-off score of at least 8 for each subscale will be used as
an indication of caseness of depression and/or anxiety.
HADS is likely to be the primary outcome in the main trial.
Brief Pain Inventory (BPI, [33]) Pain severity/intensity
as well as pain interference with daily life will be assessed
with this numerical rating scale (scaled from 0 to 10). This
scale assesses the average pain, which is associated with PD
according to the patient’s point of view. Thereby, 0 repre-
sents no pain and 10 the most painful sensation imaginable.
Fatigue Severity Scale (FSS, [34]) This nine-item scale
will be used to assess the impact of fatigue on the daily living
of patients. It comprises three items related to physical
Bogosian et al. Pilot and Feasibility Studies  (2017) 3:4 Page 7 of 13
impact, three items to the psychological environment, and
the remaining three are more generic. Each item is rated on
a 7-point Likert scale (1 = completely disagree–7 = com-
pletely agree). Mean scores of 4 or more define significant
fatigue.
Insomnia Severity Index (ISI, [35]) This self-report
measure consists of seven items that assess the nature, se-
verity, and impact of insomnia in the last 2 weeks. Each
item is rated on a 5-point Likert scale (0 = not at all–4 =
extremely) with total scores ranging from 0 to 28, whereby
higher scores indicate greater insomnia severity.
Parkinson’s Disease Activities of Daily Living Scale
(PADLS, [36]) This self-report scale will assess difficulties
in daily activities due to PD. This five-item scale provides
a single global rating of how patients perceive their illness,
with higher scores indicating greater difficulty in activities
of daily living.
Process mechanism measures
We will also assess some mindfulness-related mechanisms.
Participants will be asked to keep a diary in which they will
monitor the frequency and duration of their home mindful-
ness practice.
Self-Compassion Scale—Short Form (SCS-SF, [37])
Research has shown that self-compassion is associated
with psychological well-being and suggests that self-
compassion might be an important protective factor,
fostering emotional resilience (see Neff, [39], for a re-
view). Self-compassion will be assessed using 12 items
and a total score will be generated. This short form of
the SCS demonstrates adequate internal consistency
(Cronbach’s alpha ≥ 0.86) and a near-perfect correlation
with the long form SCS (r ≥ 0.97) [37].
Experiences Questionnaire (EQ, [40]) This question-
naire measures decentering, one of the process mecha-
nisms that are used during the MBI course with the
view to reduce distress. Decentering is defined as the
ability to observe one’s thoughts and feelings as tempor-
ary, objective events in the mind, as opposed to reflec-
tions of the self that are necessarily true. An initial
validation study of EQ showed that levels of decentering
among people with major depression were significantly
Table 2 Details and schedule of the MindPD trial assessment procedure
Assessments administered Screening
(week 0)
Baseline
(week 1)
Mid-intervention
(week 4)
Post-intervention
(week 8)
3-month follow-up
(week 20)
Main details sheet X
Telephone Interview for Cognitive Status Instrument modified
version (TICS-M)
X
Demographics sheet X
Primary outcome measure:
Hospital Anxiety and Depression Scale (HADS) X X X X
Secondary outcome measures:
Parkinson’s Disease Activities of Daily Living Scale (PADLS) X X X X
Brief Pain Inventory (BPI) X X X X
Fatigue Severity Scale (FSS) X X X X
Insomnia Severity Index (ISI) X X X X
Process variables:
Self-Compassion Scale (SCS) X X X X
Philadelphia Mindfulness Scale (PHLMS) X X X X
Experiences Questionnaire (EQ) X X X X
Acceptance Action Questionnaire (AAQ-II) X X X X
Intolerance of Uncertainty Scale (IUS-12) X X X X
Health economics variables:
Subjective Well-Being questionnaire (SWB) X X X
EuroQoL and visual analog scale (EQ-5D-3L and VAS) X X X
ICEpop CAPability Measure for Adults (ICECAP-A) X X X
Adult Social Care Outcomes Toolkit (ASCOT) X X X
Home practice X X
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and negatively correlated with concurrent self-report (r =
−0.46) and clinician-assessed (r = −0.31) levels of depres-
sion symptoms.
Acceptance Action Questionnaire (AAQ-II, [41]) The
AAQ-II assesses acceptance, experiential avoidance, and
psychological inflexibility, which is related to a range of out-
come, from mental health to work absence rates. Results
from 2816 participants across six samples indicate the satis-
factory structure, reliability, and validity of this measure [42].
Philadelphia Mindfulness Scale (PHLMS, [43]) This
20-item scale comprises two subscales: awareness and
acceptance. The awareness subscale assesses noticing
and being aware of thoughts, felons, perceptions, and
body sensations, while the acceptance subscale assesses
experiential avoidance.
Intolerance of Uncertainty Scale—Short Version
(IUS-12, [44]) The 12-item scale measures the partici-
pant’s response to uncertainty, ambiguous situations,
and the future. It is rated on a 5-point Likert scale ran-
ging from 1 (not at all characteristic of me) to 5 (entirely
characteristic of me).
Home practice diary Participants will be asked to keep
a diary (either on paper or online) in which they will
monitor the frequency and the duration of their home
mindfulness practice.
Health economics measures
Participants of both arms will be measured using the as-
sessments described below.
Subjective well-being (SWB, [45]) These four items
from the Office of National Integrated Household Survey,
2011, will assess feelings regarding participants’ life satis-
faction, happiness, anxiety, and life as something worth-
while at baseline, pre-, and post-intervention time points.
EuroQol five-dimensional questionnaire and visual
analog scale (EQ-5D-3L and EQ-VAS, [46, 47]) The
EQ-5D-3L is a five-item composite measure, and the
EQ-VAS is a visual analog scale, both developed by the
EuroQol Group. The EQ-5D-3L consists of five dimen-
sions (mobility, self-care, usual activities, pain/discomfort,
and anxiety/depression) each with three levels of prob-
lems. Both the EQ-5D-3L and EQ-VAS will be used to as-
sess participants’ quality of life.
The ICEpop CAPability measure for Adults (ICE-
CAP-A, [48]) and the Adult Social Care Outcomes
Toolkit (ASCOT, [49]) The ICECAP-A is a measure of
capability for the general adult population (+18) com-
prised of five attributes of well-being (attachment, stabil-
ity, achievement, enjoyment, and autonomy); the ASCOT
is a self-compliance questionnaire comprised of eight at-
tributes (personal cleanliness and comfort, food and
drink, control over daily life, personal safety, accommo-
dation cleanliness and comfort, social participation and
involvement, occupation, and dignity).
Feedback interview procedure
At the end of the 8-week intervention period, partici-
pants, in the MBI group, will also be included to be
interviewed by an MSc health psychology student
who has not had any involvement in other aspects of
the trial. Participants will be asked to give open and
Table 3 Topic guide for participants’ experiences with the mindfulness course
Questions Prompts
1. First of all, can you start by telling me what you were expecting
from the mindfulness sessions?
-What did you think the programme would be like?
-In what ways (if any) did you think it might help you?
2. How did you find the programme overall? -Tell me how you found your first session
-Tell me about the other sessions
-Tell me how you found the homework tasks
3. Can you tell me what you liked about the programme? -What was helpful? Why? How?
-Were there some sessions/some aspects that were more helpful than others?
4. Can you tell me what you disliked about the programme? -What was unhelpful? Why? How?
-Were there some sessions/some aspects that were less helpful than others?
5. Tell me about anything that you feel has changed from having
done the programme?
-Can you tell me what changed? (Anything different in your day-to-day life,
the way you are dealing with PD?)
-Can you tell me how you came to notice things changing?
-Why/how do you think things changed?
6. Do you have anything else you would like to tell me about your
experiences of this programme that have not already covered?
-What would you feed back to the people who put together the programme?
-What advice would you give to people thinking about taking part in
mindfulness-based programmes?
7. What do you think of the questionnaires used and the overall
set-up of the study?
-How did you find participating in a course over Skype?
-Any further comments regarding the questionnaires used?
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honest accounts of their experiences and opinions of
the intervention (see topic guide, Table 3). Questions
address expectations regarding the intervention, expe-
riences of MBI sessions, features of the intervention
liked and disliked, and the process of change (or not)
as a result of the course. Each interview will be digit-
ally recorded. Interviews will be anonymised and
transcribed; any information that may compromise
confidentiality will be omitted before the transcripts
come to the research team.
Data protection and confidentiality
Recordings, transcripts, and documentation relating to
participants will be stored in a locked filing cabinet at
PI’s office at City, University of London and only avail-
able to the research team. Each participant will be
assigned a study ID that will be kept separate to a list
with ID and names. Data stored on the computer will be
password protected, and only members of the research
team will know the password. In the write-up of the re-
search, names and any other identifiable information will
not be used.
Blinding
The research trial coordinator will coordinate all assess-
ment procedures. Data will be downloaded in an Excel
spreadsheet by the trial coordinator. All assessments are
based on self-report online assessments, rather than rated
or imputing by a member of the research team. Therefore,
influences of observer biases are not expected.
Due to the nature of the intervention, it is not possible
to blind the principal investigator, as she will be deliver-
ing the MBI sessions. It is also not possible to blind par-
ticipants to intervention allocation. During statistical
analysis, the intervention groups will be assigned a code
rather than their name (i.e. WLC vs. MBI) so that the
researchers are unaware of what the intervention group
code represents.
Compliance
This pilot trial will be conducted in compliance with the
Declaration of Helsinki, Medical Research Council Good
Clinical Practice (GCP) guidance, the Data Protection Act
(1998), the National Research Ethics Service (NRES) ap-
provals, National Health Service (NHS) Trust regulations,
and other regulatory requirements as appropriate. The final
trial publication will include the items recommended under
the CONSORT statement for randomised trials [50].
Participant safety
This MBI course is expected to be of low risk to partici-
pants. Mindfulness approaches are non-invasive and have
been previously used successfully in chronic illness popu-
lations [14]. If AB is concerned about a patient’s safety, a
referral will be made to ensure the participant gets the
support he/she needs.
Withdrawals from MBI course
If a participant expresses the wish to withdraw from the
MBI course, AB will contact the participant to ascertain
the reason for drop-out if the participant is willing to
share this.
The reason for withdrawal (e.g. adverse events, illness
progression, inability to adhere, inability to attend) will
be discussed with all team members, and the informa-
tion will be recorded as appropriate. Again, if it is felt
that a participant should be withdrawn from the course,
this will be discussed in a meeting with all the members
of the research team.
Data analysis plan
Quantitative analysis plan
Statistical analysis will be carried out in STATA. Descrip-
tive statistics (mean, median, standard deviation) will be
calculated for all demographics and clinical variables. All
group comparisons will be carried out on an intention-to-
treat basis, that is participants will be analysed in the
group to which they were randomised. Descriptive results
concerning recruitment numbers, completions, drop-out
rates, and missing data will be calculated and reported.
The quantitative data will be summarised with standard
descriptive measures for each group separately to deter-
mine potential change within group over time. Continu-
ous variables will be summarised by their mean and
standard deviation, categorical variables as numbers and
percentages, and presented with 95% confidence intervals.
With the aim of identifying a potential response shift in
some of the participants, a retrospective measurement will
also be implemented. In particular, then-test questions will
be added to the post-intervention and 20-week follow-up
questionnaires for several outcome variables. Both mea-
surements of the effect of the course (prospective and
retrospective) will be compared, in order to add robust-
ness to the results. We will also assess the sensitivity of
the results to excluding patients who did not receive a suf-
ficient number of MBI sessions or those who had little
meditation home practice.
Economic evaluation plan
Cost comparisons will be made between the mindfulness
course and the standard care. Service cost data will be
combined with the primary outcome measures (HADS)
and quality-of-life measures generated from the EQ-
5D-3L to assess cost-effectiveness. If the intervention
has lower costs and better outcomes, then it will be
‘dominant’. In the event of the intervention having higher
service costs and better outcomes, cost-effectiveness will
be assessed using incremental cost-effectiveness ratios. To
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address uncertainty in cost and outcome differences, we
will run different sensitivity analyses, as tornado diagrams,
worst-best scenarios or cost-effectiveness acceptability
curves. The results of this economic evaluation should be
treated with caution as the study is underpowered. How-
ever, the results will give an indication of the potential
cost-effectiveness of the mindfulness intervention.
Qualitative analysis plan
The interviews will be analysed using inductive thematic
analysis. The inductive analysis is a process of coding
the data without trying to fit it into a pre-existing coding
frame or the researcher’s analytic preconceptions [51].
The analysis will be conducted following Braun and
Clarke’s guidelines [52]. The analysis of the transcripts
will be conducted in parallel with ongoing data collec-
tion. First, each coding unit in the first transcript will be
given a code name, using vocabulary as close as possible
to that used by participants themselves [53] to avoid pre-
maturely importing preconceptions into the analysis.
This procedure will be repeated on the second tran-
script. When the same themes reoccur, they will be pro-
vided with the same label. Initial codes will then be
applied systematically to the entire dataset, giving full
and equal attention to each data item. As data analysis,
proceeds codes will be re-defined as new and alternative
themes arise. Earlier transcripts will be re-coded as
codes are developed and refined. During this analysis,
the validity of individual themes in relation to the
dataset will be considered and also whether the themes
reflect the dataset as a whole. A detailed paper trail will
record the development of the codes and the relation-
ship between the raw data and the refined themes and
codes. Further, framework analysis techniques [54] will
be used, where the final codes will be tabulated to in-
spect the data for patterns and relationships in the
themes between people with PD.
Discussion
Mindfulness-based interventions have been shown to
effectively reduce anxiety, depression, and pain in pa-
tients with chronic physical illnesses, including PD [14].
Mindfulness-based interventions have been tradition-
ally delivered in a face-to-face group setting [55]. This
pilot trial will look specifically at assisting psychological
adjustment for people with PD and is conducted in
preparation of an efficacy study for an online MBI in
PD. The distance delivery of this trial means that we
are offering psychological support to a group of pa-
tients who would not otherwise routinely have formal
access to psychological interventions but who nonethe-
less are faced with considerable psychological chal-
lenges. With this study, we will explore different ways
to deliver group psychological interventions and we will
enrich our knowledge on the specific needs and chal-
lenges faced by people affected by PD as well as how
best to address these needs.
Some limitations of the current study need to be ac-
knowledged. First, we will not have a large enough sam-
ple to account for the heterogeneity in the non-motor
challenges that people with PD face. Therefore, we will
not be able to make sub-group comparisons of the po-
tential effectiveness of the interventions for people who
entered the trial with different non-motor challenges.
Further, a WLC group can induce nocebo effects [56],
inflating the effectiveness of the intervention. Any wors-
ening of symptoms for the WLC group will be reported
and suggestions will be made for more appropriate con-
trols in a future larger trial. Also, the total HADS [31]
score may not be the most appropriate tool to detect
caseness of depression and anxiety [57]. However, it was
chosen since HADS measures anxiety and depression
without confounding by somatic symptoms of the phys-
ical disorder, in contrast to other depression and anxiety
scales that include items like insomnia, retardation of
psychomotor, tremor, dry mouth, muscle aches, loss of
energy, and fatigue. These items although they are an in-
dication of anxiety or depression, they can also be symp-
toms of PD and not a reflection of anxiety or depression.
There are also some validation studies for HADS show-
ing good psychometric properties [58–61]. In addition,
HADS will potentially be chosen as the primary out-
come of the intervention and it was important to choose
a measure that is sensitive to change both during the
course of an illness and in response to medical or psy-
chological intervention [33, 62]. HADS is also relatively
short and easy to administer. Finally, Skype calls depend
on the strength of the internet connection and can inter-
rupt therapy sessions. AB has experience delivering these
courses over Skype without excessive technical problems
[23, 63]. AB usually incorporates any disruptions or lack
of quality as examples that participants could use to prac-
tise staying with difficulties and identify thoughts arising
when there is frustration, so these interruptions become
part of the mindfulness learnings. The qualitative inter-
views with participants at the end of the courses will help
us explore experiences of the course and the Skype deliv-
ery. These interviews will direct us to potential changes in
the future courses.
Nevertheless, this pilot trial will answer important
questions about the feasibility of procedures and pro-
cesses as well as the potential efficacy of an 8-week
distance-delivered mindfulness course in reducing dis-
tress and increasing the quality of life. If the results
show that this intervention is feasible and potential
effective for people with PD, a grant will be prepared
for a large randomised control trial which will aim to
assess the effectiveness of this intervention on a
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representative sample and compared against an active
control group. We will also explore the role of different
‘active ingredients’ of mindfulness-based approaches
such as acceptance, self-compassion, decentering, and
cultivating mindfulness skills to determine how mind-
fulness interventions work and which are the most im-
portant components of these interventions regarding
changes in outcome measure. Further, this pilot trial will
provide some indication regarding the cost-effectiveness
of the intervention and its acceptability to patients.
This pilot trial is set up to be methodologically robust
and to conform to CONSORT guidelines. We have taken
care to address key sources of bias; the MBI for PD course
will be subject to ongoing supervision to ensure therapy
fidelity, and this will also be checked post-therapy by inde-
pendent raters. The assessments of patient outcomes are
self-reported and collected by an independent researcher
who is uninvolved in therapy delivery. The MBI trial for
PD also benefits from service-user input from the early
stages of therapy design and manual development, right
through to the in-depth evaluation of the MBI sessions.
The data from the feedback interviews will be particularly
important in guiding any changes to the MBI format.
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